GlassScriptPhysician profile
Thomas M Chin
NPI 1790840361
$6,065.78
in general payments reported to CMS, 2019-2025
27 companies · $2,056 in 2025
The $2,056 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $37.31 · 2021: $563 · 2022: $597 · 2023: $914 · 2024: $1,103 · 2025: $2,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,072.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,432.29 | 2021-2025 | Airsupra, Breztri, Fasenra |
| Pfizer INC. | $1,000.40 | 2019-2025 | |
| Incyte Corporation | $441.95 | 2022-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $355.22 | 2021-2025 | |
| Ars Pharmaceuticals Operations, INC. | $300.00 | 2025 | Neffy |
| Leo Pharma INC. | $266.87 | 2023-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $259.39 | 2019-2024 | |
| Alk-Abello, INC | $244.88 | 2021-2023 | Ragwitek, Odactra, Grastek |
| Regeneron Healthcare Solutions, INC. | $217.36 | 2023-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $179.76 | 2024-2025 | |
| Celgene Corporation | $173.43 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $159.45 | 2019-2022 | |
| Glaxosmithkline, LLC. | $136.53 | 2021-2024 | Arexvy |
| Journey Medical Corporation | $124.85 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.05 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $118.00 | 2023-2024 | Vtama |
| Insmed, INC. | $114.17 | 2025 | Brinsupri |
| Aclaris Therapeutics, INC. | $104.44 | 2019 | |
| Ucb, INC. | $65.76 | 2024 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $61.85 | 2024 | Sotyktu |
| Genentech USA, INC. | $50.03 | 2021 | |
| Almirall LLC | $37.69 | 2021-2024 | Seysara |
| Abbvie INC. | $36.72 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.02 | 2019 | |
| Optinose US, INC. | $17.08 | 2019 | |
| Botanix Sb INC | $16.70 | 2025 | Sofdra |
| Organon LLC | $8.89 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Chin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.